Allergan

Latest stories

1h
USA Today
White House and business sector battle over arbitrationissued new rules that torpedoed U.S. pharmaceutical giant Pfizer's $160 billion
White House and business sector battle over arbitration
USA Today / Posted an hour ago
issued new rules that torpedoed U.S. pharmaceutical giant Pfizer's $160 billion merger with Ireland-headquartered rival Allergan. Similarly, the Department of Justice filed a federal lawsuit aimed at blocking oilfield services firm Halliburton's... Read more
6 related stories
10h
Business Standard India
Pfizer approaches Medivation about potential take-overmark another attempt at building scale in patented drugs after it scrapped its
Pfizer approaches Medivation about potential take-over
Business Standard India / Posted 10 hours ago
mark another attempt at building scale in patented drugs after it scrapped its $160-billion acquisition of Dublin-based Allergan Plc last month. The breakdown came days after the US Treasury issued new rules that weighed on Pfizer's ability to... Read more
9 related stories
11h
5KSDK St. Louis
CEOs gloomy about economyin foreign countries, thus allowing them to pay taxes to the foreign government
CEOs gloomy about economy
5KSDK St. Louis / Posted 11 hours ago
in foreign countries, thus allowing them to pay taxes to the foreign government at a lower rate. The $160 billion Pfizer-Allergan mergeris the most recent example. Health Care/Labor Costs - Wage pressures have not increased across the board but... Read more
13h
Accounting Today
Coke Bottler's Merger Might Lose Tax Gain to Inversion Ruleslast year through a $53 billion merger with Covidien Plc. New York-based Pfizer
Coke Bottler's Merger Might Lose Tax Gain to Inversion Rules
Accounting Today / Posted 13 hours ago
last year through a $53 billion merger with Covidien Plc. New York-based Pfizer Inc.’s $160 billion plan to invert with Allergan Plc of Ireland was canceled last month because of another Treasury proposal that would limit a company’s ability to... Read more
14h
The Globe and Mail
Biotech stock swoon sparks buyout interest: Janus managerMedivation to express interest in an acquisition. The U.S. government’s derail
Biotech stock swoon sparks buyout interest: Janus manager
The Globe and Mail / Posted 14 hours ago
Medivation to express interest in an acquisition. The U.S. government’s derailment of Pfizer’s $160-billion acquisition of Allergan Plc last month has raised expectations that both drugmakers will now seek smaller transactions. Allergan will be... Read more
2 related stories
15h
San Antonio Express-News
Allergan PLC Shares Shed 19% in April After Being Blindsided by the U.S. TreasuryWhat: Shares of Irish-based pharmaceutical giant Allergan , which is perhaps be
Allergan PLC Shares Shed 19% in April After Being Blindsided by the U.S. Treasury
San Antonio Express-News / Posted 15 hours ago
What: Shares of Irish-based pharmaceutical giant Allergan , which is perhaps best known for its dermatology and aesthetic product line -- which includes Botox -- shed 19% of their value in April, according to data from S&P Global Market Intelligence.... Read more
16h
Zero Hedge
As The Sohn Conference Begins, This Is How Last Year's Hedge Fund Picks Didis never the case and instead more clustering and "hedge fund hoteling" ensues,
As The Sohn Conference Begins, This Is How Last Year's Hedge Fund Picks Did
Zero Hedge / Posted 16 hours ago
is never the case and instead more clustering and "hedge fund hoteling" ensues, leading to violent blowups a la Valeant and Allergan, also leading to questions why hedge funds are "suddenly" a dying breed. David Einhorn of Greenlight... Read more
3 related stories
18h
Channel NewsAsia
Biotech stock swoon sparks buyout interest: investorbidders could be interested in the company. The U.S. government's derailment o
Biotech stock swoon sparks buyout interest: investor
Channel NewsAsia / Posted 18 hours ago
bidders could be interested in the company. The U.S. government's derailment of Pfizer Inc's US$160 billion acquisition of Allergan Plc last month has raised expectations that both drugmakers will now seek smaller transactions. Allergan will be... Read more
2 related stories
19h
Reuters
Biotech stock swoon sparks buyout interest: investorcould be interested in the company. The U.S. government's derailment of Pfizer
Biotech stock swoon sparks buyout interest: investor
Reuters / Posted 19 hours ago
could be interested in the company. The U.S. government's derailment of Pfizer Inc's (PFE.N) $160 billion acquisition of Allergan Plc (AGN.N) last month has raised expectations that both drugmakers will now seek smaller transactions. Allergan... Read more
2 related stories
21h
Arkansas Democrat-Gazette
Buoyed by sales rise, lower taxes, Pfizer's net income up 27%sending shares up more than 3 percent. Four weeks after dropping its record $1
Buoyed by sales rise, lower taxes, Pfizer's net income up 27%
Arkansas Democrat-Gazette / Posted 21 hours ago
sending shares up more than 3 percent. Four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan PLC and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. surprised... Read more
36 related stories
21h
Fortune
Now It’s Pfizer That Wants to Buy Cancer Drug Maker Medivationmark another attempt at building scale in patented drugs after it scrapped its
Now It’s Pfizer That Wants to Buy Cancer Drug Maker Medivation
Fortune / Posted 21 hours ago
mark another attempt at building scale in patented drugs after it scrapped its $160 billion acquisition of Dublin-based Allergan last month. The breakdown came days after the U.S. Treasury issued new rules that weighed on Pfizer’s ability to... Read more
9 related stories
1d
Zawya
Economic growth concerns sink stocksfor the year. Its quarterly profit and revenue rose sharply. The drug maker scr
Economic growth concerns sink stocks
Zawya / Posted yesterday
for the year. Its quarterly profit and revenue rose sharply. The drug maker scrapped a $160 billion merger deal with Allergan last month. Another company that had to abandon its merger agreement, Halliburton, said it'll consider acquisitions... Read more
1d
The Star
Pfizer approaches Medivation about potential takeovermark another attempt at building scale in patented drugs after it scrapped its
Pfizer approaches Medivation about potential takeover
The Star / Posted yesterday
mark another attempt at building scale in patented drugs after it scrapped its US$160 billion acquisition of Dublin-based Allergan Plc last month. The breakdown came days after the US Treasury issued new rules that weighed on Pfizer's ability to... Read more
9 related stories
1d
Boston Globe
Pfizer CEO Looks for More Deals as Drugmaker Mulls Splitthat are close to hitting the market, while considering a split of the business
Pfizer CEO Looks for More Deals as Drugmaker Mulls Split
Boston Globe / Posted yesterday
that are close to hitting the market, while considering a split of the business in the wake of failed takeover attempts of Allergan PLC and AstraZeneca PLC. “At this stage I would chose a late-stage asset because I think we have a lot of products... Read more
2 related stories
1d
ABC News
The Clintons Criticize Companies That Have Donated to Their Foundationa total of $1,000,001 and $5 million since 2005, according to Minassian. Back
The Clintons Criticize Companies That Have Donated to Their Foundation
ABC News / Posted yesterday
a total of $1,000,001 and $5 million since 2005, according to Minassian. Back in December, Hillary Clinton said the Pfizer-Allergan merger "gets my blood going” to a crowd in Urbandale, Iowa. While the Johnson Controls merger with Tyco is still... Read more
1d
The Star
Global M&A slowdown clouds stocksHalliburton scrapping plans to acquire Baker Hughes and Pfizer
Global M&A slowdown clouds stocks
The Star / Posted yesterday
Halliburton scrapping plans to acquire Baker Hughes and Pfizer giving up its planned takeover of Allergan . Both deals collapsed under regulatory scrutiny. "It does concern me that M&A has fallen; that suggests... Read more
2 related stories
1d
FOX Business
9 Figures That Sum Up Pfizer, Inc.'s First Quarterdevelopment could make it one of the biggest biosimilar drugmakers on the plane
9 Figures That Sum Up Pfizer, Inc.'s First Quarter
FOX Business / Posted yesterday
development could make it one of the biggest biosimilar drugmakers on the planet by then. 23.8%. Pfizer's hopes to acquire Allergan plcin an attempt to shift its tax address from the U.S. to low-cost Ireland were dashed by regulators last quarter,... Read more
3 related stories
1d
FOX Business
9 Figures That Sum Up Pfizer, Inc.'s First Quarterdevelopment could make it one of the biggest biosimilar drugmakers on the plane
9 Figures That Sum Up Pfizer, Inc.'s First Quarter
FOX Business / Posted yesterday
development could make it one of the biggest biosimilar drugmakers on the planet by then. 23.8%. Pfizer's hopes to acquire Allergan plcin an attempt to shift its tax address from the U.S. to low-cost Ireland were dashed by regulators last quarter,... Read more
3 related stories
1d
Channel NewsAsia
Pfizer approaches Medivation about potential takeovermark another attempt at building scale in patented drugs after it scrapped its
Pfizer approaches Medivation about potential takeover
Channel NewsAsia / Posted yesterday
mark another attempt at building scale in patented drugs after it scrapped its US$160 billion acquisition of Dublin-based Allergan Plc last month. The breakdown came days after the U.S. Treasury issued new rules that weighed on Pfizer's ability... Read more
9 related stories
1d
Los Angeles Times
Treasury Secretary Jack Lew: Puerto Rico crisis is 'immediate and real'U.S. Regulations issued by the Treasury earlier this year succeeded in quashin
Treasury Secretary Jack Lew: Puerto Rico crisis is 'immediate and real'
Los Angeles Times / Posted yesterday
U.S. Regulations issued by the Treasury earlier this year succeeded in quashing a $160-billion merger between Pfizer and Allergan, through which Pfizer would have changed its legal domicile from New York to Allergan's home in Ireland. But Lew... Read more
294 related stories
1d
Reuters
Pfizer approaches Medivation about potential takeovermark another attempt at building scale in patented drugs after it scrapped its
Pfizer approaches Medivation about potential takeover
Reuters / Posted yesterday
mark another attempt at building scale in patented drugs after it scrapped its $160 billion acquisition of Dublin-based Allergan Plc (AGN.N) last month. The breakdown came days after the U.S. Treasury issued new rules that weighed on Pfizer's... Read more
9 related stories
1d
Reuters UK Edition
Economic growth concerns sink stocksfor the year. Its quarterly profit and revenue rose sharply. The drug maker scr
Economic growth concerns sink stocks
Reuters UK Edition / Posted yesterday
for the year. Its quarterly profit and revenue rose sharply. The drug maker scrapped a $160 billion merger deal with Allergan last month. Another company that had to abandon its merger agreement, Halliburton, said it'll consider acquisitions... Read more
1d
Daily Herald
Business Highlightssending shares up more than 3 percent. Four weeks after dropping its record $1
Business Highlights
Daily Herald / Posted yesterday
sending shares up more than 3 percent. Four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan PLC and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. surprised... Read more
1d
Reuters
Pfizer CEO still interested in deals after losing Allerganofficer of Pfizer, speaks at a news conference in New York November 5, 2013. N
Pfizer CEO still interested in deals after losing Allergan
Reuters / Posted yesterday
officer of Pfizer, speaks at a news conference in New York November 5, 2013. NEW YORK After a planned purchase of Allergan Plc (AGN.N) was scuttled by the U.S. government, Pfizer (PFE.N) Chief Executive Ian Read on Tuesday said he would... Read more
2 related stories
1d
Channel NewsAsia
Pfizer CEO still interested in deals after losing AllerganNEW YORK: After a planned purchase of Allergan Plc was scuttled by the U.S. gov
Pfizer CEO still interested in deals after losing Allergan
Channel NewsAsia / Posted yesterday
NEW YORK: After a planned purchase of Allergan Plc was scuttled by the U.S. government, Pfizer Chief Executive Ian Read on Tuesday said he would consider another merger of any size, at any time, as long as the deal makes sense. But he said Pfizer is... Read more
2 related stories
1d
Channel NewsAsia
M&A slowdown clouds Wall Street view on stocksapart this year with Halliburton scrapping plans to acquire Baker Hughes and Pf
M&A slowdown clouds Wall Street view on stocks
Channel NewsAsia / Posted yesterday
apart this year with Halliburton scrapping plans to acquire Baker Hughes and Pfizer giving up its planned takeover of Allergan . Both deals collapsed under regulatory scrutiny. "It does concern me that M&A has fallen; that suggests market... Read more
2 related stories
1d
Reuters
M&A slowdown clouds Wall Street view on stocksHalliburton (HAL.N) scrapping plans to acquire Baker Hughes (BHI.N) and Pfizer
M&A slowdown clouds Wall Street view on stocks
Reuters / Posted yesterday
Halliburton (HAL.N) scrapping plans to acquire Baker Hughes (BHI.N) and Pfizer (PFE.N) giving up its planned takeover of Allergan (AGN.N). Both deals collapsed under regulatory scrutiny. "It does concern me that M&A has fallen; that suggests... Read more
2 related stories
1d
Daily Herald
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
Daily Herald / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. on Tuesday... Read more
36 related stories
1d
Channel NewsAsia
New drugs fuel strong Pfizer results; company raises 2016 forecastsREUTERS: Pfizer Inc, which last month abandoned its US$160 billion quest for Al
New drugs fuel strong Pfizer results; company raises 2016 forecasts
Channel NewsAsia / Posted yesterday
REUTERS: Pfizer Inc, which last month abandoned its US$160 billion quest for Allergan Inc, reported quarterly results that blew past analyst estimates on sales of its new cancer and arthritis treatments and the acquisition last year of hospital... Read more
36 related stories
1d
Channel NewsAsia
Big pharma dominates ranking of stocks with best five-year returnscompany Regeneron Pharmaceuticals , which had an average annual total share ret
Big pharma dominates ranking of stocks with best five-year returns
Channel NewsAsia / Posted yesterday
company Regeneron Pharmaceuticals , which had an average annual total share return of 75.3 percent, was the top performer. Allergan and Gilead Sciences , with 43.3 percent and 41.4 percent average annual returns, respectively, took second and third... Read more
1d
The Columbus Dispatch
Pfizer tops earnings forecasts on higher sales, lower taxes3 percent in morning trading Tuesday. Just four weeks after dropping its recor
Pfizer tops earnings forecasts on higher sales, lower taxes
The Columbus Dispatch / Posted yesterday
3 percent in morning trading Tuesday. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. surprised... Read more
36 related stories
1d
Reuters
Big pharma dominates ranking of stocks with best five-year returnsTraders work at the post where Allergan stock is traded on the floor of the New
Big pharma dominates ranking of stocks with best five-year returns
Reuters / Posted yesterday
Traders work at the post where Allergan stock is traded on the floor of the New York Stock Exchange (NYSE) April 6, 2016. NEW YORK U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year... Read more
1d
Channel NewsAsia
New drugs help sparkling Pfizer results; company raises 2016 forecastsstrategy might change, following the company's decision last month to abandon i
New drugs help sparkling Pfizer results; company raises 2016 forecasts
Channel NewsAsia / Posted yesterday
strategy might change, following the company's decision last month to abandon its planned US$160 billion acquisition of Allergan Inc. Pfizer walked away after the U.S. Treasury issued new rules curbing tax inversion deals, under which American... Read more
36 related stories
1d
The Irish Times
Failed Perrigo suitor Mylan sees revenues rise on generic drugs2015. Israel-based Teva, for its part, moved on to acquire the generics busine
Failed Perrigo suitor Mylan sees revenues rise on generic drugs
The Irish Times / Posted yesterday
2015. Israel-based Teva, for its part, moved on to acquire the generics business of another Irish-domiciled business, Allergan before a move to merge the remaining parts of Allergan with industry heavyweight Pfizer became the most notable... Read more
2 related stories
1d
Salon.com
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
Salon.com / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. on Tuesday... Read more
36 related stories
1d
Spartanburg Herald-Journal
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
Spartanburg Herald-Journal / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. on Tuesday... Read more
36 related stories
1d
Island Packet
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
Island Packet / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. surprised... Read more
36 related stories
1d
San Francisco Chronicle
Pfizer tops Street 1Q forecasts on higher sales, lower taxesciting its strong performance in the quarter and an improved business outlook.
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
San Francisco Chronicle / Posted yesterday
citing its strong performance in the quarter and an improved business outlook. The company had made a big bet on the Allergan deal, saying it was needed to make Pfizer more competitive with European rivals who face lower tax rates. Pfizer now... Read more
36 related stories
1d
ABC News
Pfizer Tops Street 1Q Forecasts on Higher Sales, Lower Taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer Tops Street 1Q Forecasts on Higher Sales, Lower Taxes
ABC News / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. surprised... Read more
36 related stories
1d
The News-Times
Pfizer tops Street 1Q forecasts on higher sales, lower taxesciting its strong performance in the quarter and an improved business outlook.
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
The News-Times / Posted yesterday
citing its strong performance in the quarter and an improved business outlook. The company had made a big bet on the Allergan deal, saying it was needed to make Pfizer more competitive with European rivals who face lower tax rates. Pfizer now... Read more
36 related stories
1d
The Hendersonville Times-News
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
The Hendersonville Times-News / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. on Tuesday... Read more
36 related stories
1d
FOX Business
Pfizer 1Q Revenue Beats on Hospira Acquisitionitems, the company earned 67 cents per share, above the average analyst estimat
Pfizer 1Q Revenue Beats on Hospira Acquisition
FOX Business / Posted yesterday
items, the company earned 67 cents per share, above the average analyst estimate of 55 cents per share. Pfizer and Allergan walked away from their $160 billion merger in April, citing new U.S. Treasury rules aimed at blocking the deal's tax... Read more
7 related stories
1d
The Lexington Dispatch
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
The Lexington Dispatch / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. on Tuesday... Read more
36 related stories
1d
FOX Business
Pfizer 1Q Revenue Beats on Hospira Acquisitionearned 67 cents per share, above the average analyst estimate of 55 cents per s
Pfizer 1Q Revenue Beats on Hospira Acquisition
FOX Business / Posted yesterday
earned 67 cents per share, above the average analyst estimate of 55 cents per share. Continue Reading Below Pfizer and Allergan walked away from their $160 billion merger in April, citing new U.S. Treasury rules aimed at blocking the deal's tax... Read more
7 related stories
1d
Your Hometown Lima Stations
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
Your Hometown Lima Stations / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. on Tuesday... Read more
36 related stories
1d
The Wilmington Star-News
Pfizer tops Street 1Q forecasts on higher sales, lower taxesalmost 3 percent in premarket trading. Just four weeks after dropping its reco
Pfizer tops Street 1Q forecasts on higher sales, lower taxes
The Wilmington Star-News / Posted yesterday
almost 3 percent in premarket trading. Just four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York-based Pfizer Inc. on Tuesday... Read more
36 related stories
1d
The Irish Times
Pfizer revenue beats expectations on Hospira acquisitionitems, the company earned 67 cents per share, above the average analyst estimat
Pfizer revenue beats expectations on Hospira acquisition
The Irish Times / Posted yesterday
items, the company earned 67 cents per share, above the average analyst estimate of 55 cents per share. Pfizer and Allergan walked away from their $160 billion merger in April, citing new US Treasury rules aimed at blocking the deal’s tax... Read more
7 related stories
1d
CNBC
Pfizer earnings, revenue top expectationsDepartment unveiled a series of rules that effectively torpedoed a $160 billion
Pfizer earnings, revenue top expectations
CNBC / Posted yesterday
Department unveiled a series of rules that effectively torpedoed a $160 billion merger between the Dow component and Allergan. The merger would have allowed Pfizer to take advantage of Ireland's more favorable tax environment in a so-called... Read more
7 related stories
1d
Reuters
Pfizer revenue beats on Hospira acquisitionitems, the company earned 67 cents per share, above the average analyst estimat
Pfizer revenue beats on Hospira acquisition
Reuters / Posted yesterday
items, the company earned 67 cents per share, above the average analyst estimate of 55 cents per share. Pfizer and Allergan Inc (AGN.N) walked away from their $160 billion merger in April, citing new U.S. Treasury rules aimed at blocking... Read more
7 related stories
1d
FOX Business
Pfizer's 1Q EPS & Revenue Beat Estimatesearlier. Net income rose to $3.02 billion, or 49 cents per share, from $2.38 b
Pfizer's 1Q EPS & Revenue Beat Estimates
FOX Business / Posted yesterday
earlier. Net income rose to $3.02 billion, or 49 cents per share, from $2.38 billion, or 38 cents per share. Pfizer and Allergan Inc walked away from their $160 billion merger in April, citing new U.S. Treasury rules aimed at blocking the deal's... Read more
36 related stories
More

People in this news